This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Looking into the phase 2 VLA15-221 clinical trial data on Valneva's Lyme disease vaccine candidate.
Ticker(s): VALNWho's the expert?
Institution: Cooper University Health Hospital
- Primary care provider who sees 80 patients with NASH
- Assistant professor of medicine who manages patients with metabolic syndrome, DM, HTN, renal and liver disease
- Special interest in preventative care medicine
Interview Goalto discuss the current treatment landscape and the potential of VLA15, a vaccine being developed by Valneva and Pfizer for the prevention of Lyme disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
